All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
BCL-2 inhibitors
BCL-2 inhibitors
Bcl-2 is a pro-survival oncogene that promotes leukemogenesis by blocking programmed cell death. Therefore, agents designed to disrupt anti-apoptotic signaling pathways are considered for treatment of hematological malignancies, including Bcl-2 inhibitors like venetoclax. Another subfamily of ‘BH3-only’ proteins induce apoptosis by binding to BCL-2. Agonist for pro-apoptotic proteins, like ‘BH3-only’ proteins, are in development.
Save to your areas of interest